Blood 2003, 101:38–44 PubMedCrossRef

Blood 2003, 101:38–44.PubMedCrossRef selleck inhibitor 17. Ma F, Zhang SR, Ning L, Sun WX, Liang X, Zhang XY, Fu M, Lin C: Construction of eukaryotic

expression vector of murine SLC gene and characterization of its chemotactic function. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2003,19(6):528–30.PubMed 18. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, Klinakis A, Lukyanov Y, Tseng JC, Sen F, Gehrie E, Li M, Newcomb E, Zavadil J, Meruelo D, Lipp M, Ibrahim S, Efstratiadis A, Zagzag D, Bromberg JS, Dustin ML, Aifantis I: CCR7 signaling as an essential regulator of CNS infiltration in T-cell leukemia. Nature 2009,459(7249):1000–4.PubMedCrossRef 19. Stetler-Stevenson WG, Kleiner DE: Molecular biology of cancer: invasion and metastases. Philadelphia: Lippincott & Wilkins; 2001:123–36. 20. Nomura T, Hasegawa H: Chemokines and anti-cancer immunotherapy: Anti-tumor effect of EBL1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Anticancer Res 2000,20(6A):4073–4080.PubMed 21. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide-3-kinases: imp lications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17:615–675.PubMedCrossRef 22. Xu X, Sakon M, Nagano H, Hiraoka N, Yamamoto H, Hayashi N, Dono K, Nakamori S, Umeshita K, Ito Y, Matsuura N, Monden M: Akt2 expression correlates with prognosis of human hepatocellular carcinoma.

Oncol Rep 2005, 11:25–32. 23. Yamamoto Vadimezan clinical trial S, Tomita Y, Hoshida Y, Morooka T, Nagano Niclosamide H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Nutlin-3a mouse Aozasa K: Prognostic significance of activated akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004, 10:2846–2850.PubMedCrossRef 24. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005, 94:29–86.PubMedCrossRef 25. Altomare DA, Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455–7464.PubMedCrossRef 26. Nicholson KM, Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002, 14:381–395.PubMedCrossRef

27. Sánchez-Sánchez N, Riol-Blanco L, de la Rosa G, Puig-Kröger A, García-Bordas J, Martín D, Longo N, Cuadrado A, Cabañas C, Corbí AL, Sánchez-Mateos P, Rodríguez-Fernández JL: Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 2004,104(3):619.PubMedCrossRef 28. Nabeshima K, Inoue T, Shimao Y, Sameshima T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Annual 2002,52(4):255–264. 29. Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, Nakata K, Kogawa K, Koito K, Hareyama M, Himi T: Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgekin’s lymphoma. Cancer 2004, 100:356–365.PubMedCrossRef 30.

Comments are closed.